• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: NOVOCURE LTD OPTUNE; NZK

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

NOVOCURE LTD OPTUNE; NZK Back to Search Results
Model Number TFH-9000
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Convulsion, Tonic (2223)
Event Date 02/23/2015
Event Type  Injury  
Event Description
Patient with recurrent glioblastoma (gbm) began optune therapy on (b)(6) 2015.On (b)(6) 2015, the patient was hospitalized due to new onset seizure.Prior to admission, patient had experienced a 20 minute episode of confusion and visual disturbance.Patient was admitted for neurological work-up and mri scan (results not provided).Optune therapy was temporarily discontinued upon admission.Ophthalmologic consultation found left lower homonymous quadrantanopia with no papilledema.Brain ct scan did not show evidence of disease progression.Patient was treated with levetiracetam 500 mg bid and dexamethasone dose was increased to 6 mg daily.Patient improved with no further seizure activity.Patient was discharged on (b)(6) 2015 and optune therapy was restarted.Per the prescribing physician, the events were the results of an epileptiform attack related to the patient's underlying gbm.
 
Manufacturer Narrative
Novocure agrees with the prescribing physician that the seizure was related to underlying gbm.Seizure was not related to optune.Patient continued with optune therapy with no further seizure activity reported.Seizures were reported as adverse events on the pivotal phase iii recurrent gbm trial in both arms of the trial (9% and 4% in optune therapy and chemotherapy arms respectively).None of these seizures were considered device or chemotherapy related by investigators.Seizures are a known complication of the underlying disease (recurrent gbm).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OPTUNE
Type of Device
NZK
Manufacturer (Section D)
NOVOCURE LTD
haifa
IS 
Manufacturer Contact
eilon kirson
topaz bldg. matam center
4th floor
haifa 
IS  
4851204
MDR Report Key4739540
MDR Text Key5890016
Report Number3009453079-2015-00054
Device Sequence Number1
Product Code NZK
Combination Product (y/n)N
Reporter Country CodeIS
PMA/PMN Number
P100034
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Physician
Type of Report Initial
Report Date 03/31/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Lay User/Patient
Device Model NumberTFH-9000
Other Device ID Number07290107980401
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 03/31/2015
Initial Date FDA Received04/29/2015
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured04/01/2014
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization;
Patient Age67 YR
-
-